Ligand Raises $700M Via 0% Convertible Notes, Adds Note Hedges and $524.34 Strike Warrants
I'm LongbridgeAI, I can summarize articles.Ligand Pharmaceuticals raised $700 million through a private offering of 0% convertible senior notes due in 2031 to enhance liquidity. To mitigate potential dilution, the company entered hedge transactions covering approximately 2.09 million shares and sold warrants with a $524.34 strike price covering about 4.19 million shares. These measures aim to offset hedge costs and manage capital structure while providing financial flexibility.
Ligand Pharmaceuticals completed a $700.0 million private offering of 0.00% Convertible Senior Notes due 2031, bolstering liquidity and capital flexibility. In tandem, the company entered convertible note hedge transactions covering about 2.09 million shares to mitigate dilution and potential cash outlays upon conversion, and sold warrants with a $524.3400 strike that may be dilutive above the strike while helping offset hedge costs. The notes carry no regular interest, are senior unsecured, and are initially convertible at $334.27 per share, with redemption permitted from Sep 21, 2029 subject to stock price conditions.
Agreement 1: Ligand Pharmaceuticals Raises $700M Via 0% Convertible Notes Due 2031
- Agreement type: $700 million 0.00% Convertible Senior Notes due 2031 (Indenture)
- Counterparty: U.S. Bank Trust
- Signed / Effective: Jun 25 2026 / Jun 25 2026
- Duration / Termination: Until Sep 15 2031
- Reason: Enhance liquidity and financial flexibility
Agreement 2: Ligand Pharmaceuticals Executes Convertible Note Hedges Covering ~2.09M Shares
- Agreement type: Convertible note hedge (purchased call options)
- Counterparty: Multiple financial institutions
- Signed / Effective: Jun 22 2026 / Jun 22 2026
- Duration / Termination: Until Sep 15 2031
- Reason: Mitigate dilution from potential conversions
Agreement 3: Ligand Pharmaceuticals Sells Warrants With $524.34 Strike Covering ~4.19M Shares
- Agreement type: Warrant transactions (sold warrants)
- Counterparty: Multiple financial institutions
- Signed / Effective: Jun 22 2026 / Jun 22 2026
- Duration / Termination: Until Sep 15 2031
- Reason: Offset hedge cost; manage capital structure
Original SEC Filing: LIGAND PHARMACEUTICALS INC [ LGND ] - 8-K - Jun. 25, 2026